Aclaris aims to raise $96 million through stock offering after shares soar
Aclaris Therapeutics has priced a planned $96 million stock sale, a day after shares of the firm soared to a nearly two-and-a-half-year high.
The Wayne biopharmaceutical company's stock shot up more than 220% after it announced positive mid-stage clinical trial results for its experimental rheumatoid arthritis therapy.
On Wednesday shares closed down 4.6% to $17.97 after earlier in the day being up by a much as 10%.
Aclaris said it p lans to sell (NASDAQ: ACRS) nearly 5.5 million shares of its…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: John George Source Type: news
More News: Arthritis | Biotechnology | Clinical Trials | Health Management | Rheumatoid Arthritis | Rheumatology